source
- Otsuka’s ADHD approval opens up new drug class with $615M opportunityOtsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.
- Yarrow goes public while Otsuka receives FDA approval for new ADHD medicationYarrow Bioscience completed a merger that took the company public and will now trade under its own ticker. The firm is developing an anti-TSHR antibody aimed at treating Graves’ disease and the ass…